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Abstract
Non-Alcoholic fatty liver disease (NAFLD) is characterized by accumulation of triglycerides (TG) in hepatocytes, which may
also trigger cirrhosis. The mechanisms of NAFLD are not fully understood, but insulin resistance has been proposed as a key
determinant.Aims: To determine the TG content and long chain fatty acyl CoA composition profile in liver from obese non-
diabetic insulin resistant (IR) and lean insulin sensitive (IS) baboons in relation with hepatic and peripheral insulin sensitivity.
Methods: Twenty baboons with varying grades of adiposity were studied. Hepatic (liver) and peripheral (mainly muscle)
insulin sensitivity was measured with a euglycemic clamp and QUICKI. Liver biopsies were performed at baseline for TG
content and LCFA profile by mass spectrometry, and histological analysis. Findings were correlated with clinical and
biochemical markers of adiposity and insulin resistance.
Results: Obese IR baboons had elevated liver TG content compared to IS. Furthermore, the concentration of unsaturated
(LC-UFA) was greater than saturated (LC-SFA) fatty acyl CoA in the liver. Interestingly, LC-FA UFA and SFA correlated with
waist, BMI, insulin, NEFA, TG, QUICKI, but not M/I. Histological findings of NAFLD ranging from focal to diffuse hepatic
steatosis were found in obese IR baboons.
Conclusion: Liver TG content is closely related with both hepatic and peripheral IR, whereas liver LC-UFA and LC-SFA are
closely related only with hepatic IR in non-human primates. Mechanisms leading to the accumulation of TG, LC-UFA and an
altered UFA: LC-SFA ratio may play an important role in the pathophysiology of fatty liver disease in humans.
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Introduction
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most
common hepatic disease in both adults and children worldwide.
NAFLD may progress from steatosis to steatohepatitis (NASH),
advanced fibrosis and cirrhosis [1]. It is strongly associated to
components of the metabolic syndrome including obesity, insulin
resistance, dyslipidemia and type 2 diabetes mellitus (T2DM) [2],
and it is estimated that up to one third of the general population in
western societies may have hepatic steatosis [3]. Interestingly,
various degrees of liver steatosis are found in ,75% of obese
subjects and virtually in 100% of individuals with T2DM. NAFLD
is also associated with an increase in the risk of cardiovascular
disease and liver related all cause mortality [4,5,6].
Previous studies have shown that the main predictors of
NAFLD are increased BMI, waist circumference, triglyceride,
and GGT or ALT concentrations, but also that NAFLD is
associated with an increased AST/ALT ratio, insulin resistance,
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that insulin resistance in skeletal muscle, liver and adipose tissue
may play a concerted role in the pathogenesis of NAFLD [7,9].
Hepatic triglyceride accumulation is proportional to hepatic
insulin resistance and subjects with NAFLD/NASH have
increased circulating NEFA due to increased lipolysis and
impaired suppression of NEFA release both during clamp and
after a glucose load [10,11]. Alarmingly, NAFLD is present in
obese children that often have not only steatosis but also have
fibrosis with NASH [11,12,13].
The current knowledge about the cellular and molecular defects
of liver steatosis and fatty acid metabolism has mainly relied upon
the study of rodent models [14,15,16]. We have recently described
the baboon (Papio hamadryas sp.) as a natural non-human primate
model for the study of insulin resistance and T2DM. Non-human
primates develop features characteristic of the metabolic syn-
drome, including obesity, insulin resistance and T2DM with
insulin signaling and insulin secretory molecular defects similar to
humans [17,18,19,20]. Moreover, previous studies of gene
expression profiles using cDNA arrays have shown a great deal
of similarity to humans in the differential expression of several
novel genes and pathways in diverse tissues, and these similarities
are highly preserved at the protein level [21]. Here, we
characterized the profile of fatty acid accumulation in liver from
obese insulin resistant baboons by direct measurements of liver
TG content and their association with clinical indexes of central
(hepatic) and peripheral (muscle) insulin sensitivity/resistance.
Methods
Ethics Statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Institutional Animal Care and Use Committee of
the Texas Biomedical Research Institute (Assurance Number:
A3082-01). The study approval ID is IACUC 923 PC. After an
overnight fast (,12 h), each baboon was sedated with ketamine
hydrochloride (10 mg/kg i.m.) before arrival in the procedure
room. Endotracheal intubation was performed using disposable
cuffed tubes (6.5–8.0 mm diameter) under direct laryngoscopic
visualization, and all the animals were supported with 98–99.5%
FiO2 by a pressure controlled ventilator adjusted, as necessary, to
keep the oxygen saturation .95%. The maintenance of anesthesia
consisted of an inhaled isofluorane (0.5–1.5%) and oxygen mix and
every effort was made to minimize suffering.
Animals
Twenty nondiabetic baboons, 10 males and 10 females, ranging
over a wide span of BMI (16.5–39.5 kg/m
2) were studied. Of note,
in our facility baboons are gang housed, fed ad libitum with a
standard monkey chow diet ([22] (Table S1), and have
unrestrained physical activity. We performed clinical and
biochemical characterization, assessment of body composition by
DXA and insulin sensitivity using a euglycemic hyperinsulinemic
Table 1. Clinical and Biochemical characteristics of the study population.
Demographics/Morphometrics
Insulin resistant
(n=10)
Insulin sensitive
(n=10) P value
Age (years) 2160.8 1860.7 NS (0.249)
Gender (M/F) 4/6 6/4 NS (0.398)
Waist (cm) 65614 9 60.7 ,0.0001
BMI 2960.7 2260.5 0.005
Body fat (%) 17616 60.5 0.006
Biochemistry
FPG (mmol/l) 6.160.05 5.560.1 NS (0.19)
HbA1c (%) 4.960.3 4.560.2 NS (0.256)
FPI (pmol/l) 152.767 69.466 0.029
ALT (U/l) 31612 8 61 NS (0.409)
AST (U/l) 29613 0 61 NS (0.808)
Total cholesterol (mmol/l) 2.460.05 2.160.05 NS (0.466)
Triglycerides (mmol/l) 0.65560.02 0.560.01 NS (0.137)
LDL-cholesterol (mmol/l) 0.8560.02 0.9360.05 NS (0.738)
HDL-cholesterol (mmol/l) 1.360.02 160.02 NS (0.075)
Leptin (mg/l) 3.960.4 1.760.4 0.029
F-NEFA (mmol/l) 6356150 4416170 NS (0.127)
Indices of Insulin Resistance
AIRI 16.4655 . 1 61.9 0.043
QUICKI 0.30960.06 0.36760.08 0.02
M (mg/kgNmin
21)2 60.3 1160.7 ,0.0001
M/I (mg/kgNmin
21)/(mU/l) 160.2 560.5 ,0.0001
Hepatic Insulin Clearance (ml/m
2Nmin
21)2 3 9 623 2 5 63 0.025
FPG=fasting plasma glucose; FPI=fasting plasma insulin; NEFA=non-esterified fatty acids; AIRI=adipocyte insulin resistance index; M/I=glucose uptake/steady state
plasma insulin; QUICKI=quantitative insulin-sensitivity check index; NS=non significant. Values expressed as mean 6 SEM.
doi:10.1371/journal.pone.0027617.t001
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21) including liver biopsies prior to the
clamp in the whole group. The study population was highly
representative of the whole baboon colony, and the clinical and
biochemical characterization of the model and screening algo-
rithms have been published elsewhere [17,18]. The animals were
not euthanized at the end of the euglycaemic clamp with biopsies.
They were recovered, given appropriate veterinary care in the
animal hospital for two days after the clamp and were released in
the baboon colony.
Evaluation of Skeletal Muscle and Liver Insulin Sensitivity
In order to evaluate hepatic insulin sensitivity we used the
Quantitative Insulin-sensitivity Check Index (QUICKI) that
primarily reflects liver glucose metabolism under fasting condi-
tions. Also, we quantitated the insulin stimulated rate of glucose
uptake (mainly reflecting skeletal muscle) with the hyperinsulin-
emic euglycemic clamp as previously described [17].
During the euglycemic insulin clamp, peripheral insulin sensitiv-
ity which primarily reflects muscle glucose uptake, was calculated as
the mean rate of insulin-stimulated whole body glucose disposal (M)
during the 90–120 min time period, since at this high level of
hyperinsulinemia endogenous glucose production is expected to be
completely suppressed even in insulin resistant animals [23]. To
account for differences in circulating insulin levels among the
subjects, peripheralinsulin sensitivity wasexpressed as M/I, where I
is the steady state plasma insulin at the end of the clamp.
Since fasting glucose concentrations are mainly determined by
hepatic glucose output after an overnight fasting period, the use of
indices employing fasting plasma insulin and fasting plasma
glucose concentrations (i.e. HOMA-IR and QUICKI) provide an
estimate of insulin sensitivity in the liver. They provide an
alternative measure to the direct measurement of hepatic insulin
sensitivity by determination of glucose production with glucose
turnover studies and tracer methodology, when this gold standard
Figure 1. Liver TG content as a determinant of hepatic insulin resistance. Liver TG content in relation to insulin sensitivity level determined
by the clamp (A) and correlation with estimates of hepatic insulin sensitivity – QUICKI (B), and fasting plasma insulin (C–D) and leptin (E–F) levels in
baboons. *p,0.05.
doi:10.1371/journal.pone.0027617.g001
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sensitivity by QUICKI as 1/[log (Fasting Plasma Insulin)+log
(Fasting Plasma Glucose)], (FPI, FPG) [24,25]. Hepatic insulin
clearance was measured as previously reported [10]. Additionally,
in order to further characterize insulin sensitivity profiles in
peripheral tissues in our study population we calculated the
adipose tissue insulin resistance index as the product of fasting
NEFA6FPI, since insulin suppresses lipolysis and NEFA delivery
to circulation by adipocytes [23].
Analytical Determinations
Plasma glucose was measured by the glucose oxidase method
using a Beckman Glucose Analyzer 2 (Beckman-Coulter, Full-
erton, CA). Chemistry panels including liver enzymes were
measured with commercial kits in an ACE Clinical Chemistry
System (Alfa Wassermann Diagnostic Technologies, NJ), and
plasma insulin was measured by radioimmunoassay (Diagnostic
Products, Los Angeles, CA). Leptin was measured at baseline by
radioimmunoassay from frozen plasma aliquots as per manufac-
turer’s protocol (Millipore, St. Charles, MO). IGF-1 levels were
measured with Immulite, as per manufacturer’s protocol (Siemens
Healthcare Diagnostics, Deerfield, IL, USA).
Liver Tissue, Histology and NAFLD Scoring System
Liver biopsies were collected at 09–309–1209 during the clamp,
snap frozen in liquid nitrogen and stored at 280uC until further
use. Liver sections were placed in 10% neutral phosphate buffered
formalin, fixed overnight, processed conventionally, embedded in
paraffin, cut at 5 mm and stained with hematoxylin and eosin
(H&E) and Masson’s trichrome using standard laboratory
methods. A board certified veterinary pathologist (E.J.D) who
was blinded to clinical information and sequence of biopsy scored
each biopsy for steatosis, lobular inflammation, hepatocellular
ballooning, and fibrosis using the NAFLD Activity Score (NAS)
and Fibrosis Staging System [26].
Liver Triglyceride Measurement
Lipid extracts from previously frozen liver tissue were assayed
for triglycerides according to the manufacturer’s protocol using the
triglyceride quantification kit (BioVision, Mountain View, CA).
This assay is based on the principle that triglycerides are broken
down to non-esterified fatty acids and glycerol by lipase. The
glycerol is then oxidized to generate a reactive product that is
detected by colorimetry (spectrophotometry at l=570 nm) and
fluorescence (Ex/Em=535/587 nm). Detection range of the
assay is 2 pmol–10 nmol (or 2–10000 mM range) of triglyceride
in various samples. Monoglycerides and diglycerides are also
detected. Protein concentration was measured by the Bradford
assay (Bio-Rad) to normalize triglyceride content in liver
samples.
Measurement of Hepatic Long Chain Fatty Acyl CoA
Liquid nitrogen frozen liver samples were homogenized in
100 mM KH2PO4, pH 4.9 and 2-propanol. Heptadecanoyl CoA
was added as internal standard. Saturated (NH4)2SO4 and
acetonitrile were added for phase separation solid phase extraction
using Oligonucleotide Purification Cartridges (Applied Biosystems,
Singapore). The cartridges were washed with distilled water, and
long-chain fatty acyl CoA esters (LCFACoA) were eluted slowly
with 0.5 ml of 60% acetonitrile. The eluent was dried, and then
reconstituted in 100 ml of methanol/H2O for ESI/MS/MS
analysis. Analysis was performed on a bench top tandem mass
spectrometer API3000 (Perkin-Elmer Sciex) interfaced with a
TurboIonspray ionization source in flow injection mode. Using
negative electrospray ionization mode, LCFACoA are ionized
predominantly to a doubly charged form and yields abundant
specific product ions from CID (collision induced dissociation).
LCFACoA are quantified by monitoring [M-2H]
22/[M-H-80]
2as
previously described [27]. Electrospray ionization of the LC-CoA
esters was effected after separation and elution from a reverse-
phase (C18) column (Table S2).
Statistical analysis
Statistical calculations were performed with StatView for
Windows, (version 5.0.1, SAS Institute, Inc., Cary, NC). All data
are expressed as mean 6 SE. Measured parameters found to
have positive skewness were transformed to natural logarithms.
Student t-test or Mann-Whitney U test were used for comparisons
between insulin resistant and insulin sensitive baboons, where
appropriate. Also, coefficients of correlations between metabolic/
Table 2. Correlations between liver TG content and long
chain fatty acyl CoA with clinical and biochemical markers in
baboons.
Liver TG Content Coefficient of Correlation P
Waist 0.619 0.0028
FPI 0.869 ,0.0001
BMI 0.681 0.0006
NEFA 0.528 0.019
Plasma TG 0.455 0.043
TG/HDL 0.539 0.013
Leptin 0.774 ,0.0001
QUICKI 20.699 0.0005
M/I 20.461 0.046
Saturated LCFACoA
Waist 0.318 NS(0.17)
FPI 0.475 0.033
BMI 0.416 NS(0.068)
NEFA 0.387 NS(0.10)
Plasma TG 0.280 NS(0.17)
TG/HDL 0.467 0.037
Leptin 0.443 0.049
QUICKI 20.589 0.007
M/I 20.123 NS(0.62)
Unsaturated LCFACoA
Waist 0.389 0.027
FPI 0.438 0.05
BMI 0.515 0.019
NEFA 0.466 0.043
Plasma TG 0.320 NS(0.17)
TG/HDL 0.417 NS(0.067)
Leptin 0.377 NS(0.10)
QUICKI 20.570 0.009
M/I 20.382 NS(0.11)
Obesity and insulin resistance is significantly correlated with higher liver TG
content, and deleterious long chain fatty acyl CoA profile in baboons.
NEFA=non-esterified fatty acids; FPI=fasting plasma insulin; M/I=glucose
uptake/steady state plasma insulin, TG=triglycerides; NS=non significant.
doi:10.1371/journal.pone.0027617.t002
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and LCFCoA were determined using the Pearson or Spearman’s
methods where applicable. Lastly, we used a step-wise method to
perform a multivariate linear regression analysis to analyze the
determinants of hepatic insulin sensitivity and liver triglyceride
content.
Results
Clinical and biochemical characteristics are summarized in
Table 1. Insulin sensitivity and body fat composition were
comprised into a wide range. Baboons were divided in two groups
based on insulin sensitivity, those with insulin resistance (mean
M=260.3 mg/kg.min
21), and a control group of insulin sensitive
animals (mean M=1160.7 mg/kg.min
21). Insulin resistant
animals had increased adiposity (BMI, waist circumference and
percent body fat) when compared to controls (all p,0.01). Fasting
plasma insulin and leptin were significantly higher in the insulin
resistant group (p,0.05, Figure 1). Moreover, there was a trend
towards higher fasting plasma glucose, non-esterified fatty acids,
hemoglobin A1C and serum triglycerides concentrations in obese
insulin resistant animals. No differences were found in ALT and
AST concentrations between groups.
Liver Triglyceride Content, Adiposity and Insulin
Sensitivity
Insulin resistant animals had a ,3 fold increase in TG content
(p=0.038) compared to control baboons (Figure 1-A). Fasting
plasma insulin more strongly correlated with TG content in liver
(R
2=0.755, p,0.0001) than QUICKI which also showed a
significant correlation with TG content (R
2=0.628, p,0.0001;
Figure 1 B–D). Increased leptin concentrations were present in the
IR (Insulin Resistant) group as compared to the IS (Insulin
Sensitive) group and a strong correlation was observed between
plasma leptin levels and liver TG content in the whole study
population (R
2=0.599, p,0.0001; Figure 1-E and F). Peripheral
(muscle) insulin sensitivity also significantly correlated with liver
TG content (R=20.461, p=0.046). Liver TG content positively
correlated also with plasma triglycerides (R=0.455, p=0.043),
adipose tissue insulin resistance index (R=0.799, p=,0.0001)
and abdominal circumference (R=0.619, p=0.003) as indicated
in Table 2. IGF-1 circulating levels were ,15% lower in the IR
group as compared to the IS, although this difference was not
Figure 2. Quantification of hepatic long-chain fatty acyl CoA by ESI/MS/MS. Representative LC/MS/MS chromatogram (A) and negative ion
pairs, [M-2H]
22/[M-H-80]
2 (B) of long-chain fatty acyl CoA esters extracted from frozen baboon liver. Acyl-CoA esters were eluted on a C18 column
with a gradient from 25% to 95% organic over 8 minutes of aqueous acetonitrile (2 mM ammonium acetate). LCCoA species were quantified from
the integrated area under the curve of the corresponding ion pairs.
doi:10.1371/journal.pone.0027617.g002
Table 3. Tissue concentration of different saturated and
unsaturated long chain fatty acyl CoA (LC-FACoA) in liver from
obese insulin resistant (IR) baboons in comparison to insulin
sensitive (IS) control group.
LC-FACoA (nmol/g tissue)
IR
(n=10)
IS
(n=10) P value
16:0 (Palmitic) 561.7 4.161.5 NS (0.22)
16: 1 (Palmitoleic) 1.560.4 160.4 0.044
18:0 (Stearic) 6.561.3 6.361.3 NS (0.76)
18:1 (Oleic) 10.8647 62.8 0.029
18:2 (Linoleic) 8.362.4 6.362 0.05
18:3 (a-Linolenic) 1.860.6 1.560.6 NS (0.24)
MUFA 12.364.6 863 0.028
UFA 22.467 15.965 0.034
SFA 11.663 10.563 NS (0.41)
UFA/SFA 1.960.3 1.560.2 0.002
MUFA/SFA 1.0460.2 0.7660.2 0.002
MUFA=Monounsaturated fatty acyl CoA; UFA=Unsaturated fatty acyl CoA;
SFA=Saturated fatty acyl CoA; NS=non significant. Values are expressed as
mean 6 SD.
doi:10.1371/journal.pone.0027617.t003
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negatively with circulating TG and TG/HDL ratio, but not with
BMI, Waist, FPI, QUICKI, M/I, liver TG content, liver long
chain saturated fatty acyl CoAs (LC-SFAs) and long chain
polyunsaturated fatty acyl CoAs (LC-PUFAs) (Table S3).
Hepatic and Peripheral Insulin Sensitivity and Long Chain
Fatty Acyl CoA Concentration in the Liver
We measured the concentrations of each of the long-chain (C16
and C18, saturated and unsaturated) acyl CoA esters in the liver
tissue of all 20 baboons using LC/MS/MS. A typical electrospray
ionization (ESI)/MS/MS chromatogram and associated parent-
daughter ion pairs of the saturated (C16:0 and C18:0) and
unsaturated (C16:1, C18:1, C18:2, and C18:3) LC-FAs is shown in
Figure 2. We found increased concentrations of long chain
unsaturated fatty acyl CoA (LC-UFA) as compared to LC-SFA.
We found no significant difference in the mean value of LC-SFA
between groups (IS: 10.562.8, IR: 11.663.0 nmol/g-liver,
p=0.41), but a ,40% increase in the concentration of LC-UFA
in the liver of the IR baboons (IR: 22.467.2, IS: 15.965.4 nmol/
g-liver, p=0.034). This increase in the LC-UFA led to a higher
(p=0.002) ratio of LC-UFA to LC-SFA in the insulin resistant
baboons compared to insulin sensitive controls (1.9360.31 vs.
1.4960.20 p=0.002) as shown in Table 3.
On average, LC-UFA were ,60% of total LCFA in the IS
animals, while in IR animals the proportion was slightly but
significantly increased to ,66% (p,0.05) (Table 3). Both LC-
UFAs and LC-SFAs significantly correlated with fasting insulin,
QUICKI and TG/HDL ratio, but not with peripheral insulin
sensitivity. LC-UFAs were also significantly associated with
abdominal circumference, BMI and NEFA concentrations, and
LC-SFAs were significantly associated with leptin concentrations
(Table 2).
We also analyzed the contribution of specific LCFACoA to
hepatic and peripheral insulin sensitivity. When we analyzed each
fatty acid separately, we found that in all cases, the IR group had
higher LCFACoA levels compared with the control IS group,
although we found these differences to be statistically different for
the monounsaturated fatty acids (Table 3). Interestingly, we found
that in addition to these differences, all total saturated (palmitic
and stearic), monounsaturated (palmitoleic and oleic) and
polyunsaturated (linoleic and a-linolenic) acids negatively corre-
lated with hepatic insulin sensitivity (Figure 3). Both saturated and
polyunsaturated fatty acids correlated well also with markers of
adiposity, particularly abdominal obesity, namely waist circum-
ference, and to a lesser extent BMI. This suggests that intrahepatic
accumulation of specific fatty acids as well as triglycerides,
accounts for increased hepatic insulin resistance.
Determinants of liver triglyceride content and hepatic
insulin sensitivity
After adjusting for age, BMI, waist and triglyceride/HDL by
using a step-wise approach, the linear regression model showed
that the main determinant of hepatic insulin sensitivity (QUICKI)
was the total liver TG content (partial R=20.66, p=0.005).
Likewise, the main determinants of total TG content were
QUICKI (partial R=20.66, p=0.005), age (partial R=0.57,
p=0.02), and TG/HDL (partial R=0.48, p=0.06) explaining
approximately 70% of the variation. (Adjusted R
2=0.71,
p=0.0003). These results further emphasize the close relationship
between central obesity and total fat content in baboon liver.
Liver Histology and NAS Scoring
Both the insulin sensitive and insulin resistant baboons had an
overall normal liver architecture. Qualitative analysis of liver
histology sections found a trend towards increased focal and
Figure 3. Increased LCFAs are associated with decreased insulin sensitivity in liver. Correlation between estimated hepatic insulin
sensitivity and liver concentration of saturated (A and C), monounsaturated (B, D) and polyunsaturated (E and F) fatty acyl CoA in study population.
doi:10.1371/journal.pone.0027617.g003
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compared to insulin sensitive baboons, as determined by both
QUICKI and clamp results (Figure 4 A–D). Overall, using the
NAS scoring system we found characteristics compatible with
NAFLD without meeting criteria for NASH (supported by the
absence of liver fibrosis with Masson’s trichrome staining) in obese
insulin resistant baboons. Additionally, some insulin resistant
animals showed changes in cell morphology including ballooning,
a feature of progressing fatty liver disease (Figure 5 A–C). These
morphological findings support the strong correlation between
liver TG content and liver insulin sensitivity.
Discussion
Hepatic triglyceride accumulation in NAFLD has been shown
to be associated with an increased risk of diabetes and
cardiovascular disease and is considered the hepatic manifestation
of the metabolic syndrome X [28,29,30,31]. In this study, taking
advantage of the non-human primate baboon model of insulin
resistance and obesity, we provide direct evidence for the increased
accumulation of triglycerides in the liver and a detailed
characterization of the specific fatty acids, possibly involved in
the pathogenesis of NAFLD. We found that hepatic triglyceride
accumulation, as well as increased concentrations of saturated and
unsaturated fatty acyl CoAs, correlated well with hepatic insulin
sensitivity.
Previous studies in murine models have provided insights into
the metabolic profile of fatty liver disease [32]. The novelty of our
study relies on the fact that in the same animal we analyzed
hepatic histology, liver lipid composition, insulin sensitivity and
their relationship with clinical and anthropometric measurements
of adiposity. We believe that these findings represent an increase in
knowledge since baboons are genetically very similar to humans,
where the data available are insulin sensitivity and total hepatic
and intramyocellular fat content by indirect measurements of
magnetic resonance spectroscopy [33,34,35]. One limitation of
our analysis is that we did not obtain direct measurements of
hepatic insulin sensitivity with regard to glucose production since
we did not utilize radio-labeled 3-H-glucose. However, given the
relatively high insulin dose utilized in our clamp studies, we believe
that most, if not all hepatic glucose production was suppressed
[23]. Since direct biochemical evidence on hepatic TG content
and fatty acyl CoA composition and their correlation with direct
measures of insulin sensitivity are not available in humans, the
Figure 4. Steatosis in insulin resistant baboons. Histological sections of liver from a control insulin sensitive baboon (BMI=16.5, QUICKI=0.469,
M=16.25 mgNkg/min
21) with (A) Hematoxylin and Eosin (H&E) and (B) Masson’s Trichrome stain showing normal parenchyma architecture;
Histological sections from an insulin resistant baboon (BMI=36.5, QUICKI=0.268, M=0.25 mgNkg/min
21) showing multifocal lipid accumulation and
distension of hepatocytes characteristic of NAFLD with (C) H&E and (D) Masson’s Trichrome stains respectively.
doi:10.1371/journal.pone.0027617.g004
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pathogenesis of the human disease counterpart. Also, some
surrogate parameters have been established to analyze fatty acid
metabolism in humans such as SCD-1 activity in VLDL sub-
fractions [36,37]. The underlying mechanisms by which obesity
and insulin resistance cause NAFLD in humans are largely
unknown. Several mechanisms described in murine models and
cultured tissues could be of particular importance in the
pathogenesis of hepatic steatosis and fibrosis. While leptin and
insulin resistance are clearly associated with NAFLD, there is some
indirect evidence supporting a primary role of increased delivery
of non-esterified fatty acids to liver as a cause of hepatic steatosis in
murine models. Interestingly, a number of cell culture studies have
demonstrated that both insulin and leptin play an important role
in stimulating fibrogenesis in the liver, and recently it has been
demonstrated that fatty acids effectively trigger inflammatory
cascades by interacting with toll-like receptors (TLR)
[38,39,40,41]. In fact, evidence suggests that specific length
saturated, rather than unsaturated fatty acids (palmitic, 16:0 and
stearic, 18:0) are related to this process providing a link between
metabolism and inflammation [42].
Hepatic fat composition studies of biopsies obtained from
morbid obese subjects undergoing bariatric surgery showed that
the liver contained proportionally more palmitic (16:0), stearic
(18:0), and long polyunsaturated fatty acids than adipose tissues.
However, in that study only eight obese subjects were studied and
no lean control subjects were reported [43]. Additional data from
liver biopsies from patients affected by NAFLD undergoing
bariatric surgery, showed parallel increases in gene expression of
PPAR-c and SREBP-1c which plays a key role in liver lipogenesis,
in relation to markers of whole body insulin resistance [44]. Also in
recent years, fatty acid binding proteins have been known to play a
crucial role in obesity and glucose metabolism. The role of specific
fatty acids has been previously evaluated in murine models, and to
this extent several isomers of conjugated linoleic acid (18:2) have
been studied. While some isomers have shown a protective effect
to prevent fatty liver, others have shown a clear deleterious effect
[45,46,47,48]. Due to the well known capacity of adipose tissue to
produce hormones (adipocytokines) involved in the regulation of
energy balance and insulin action we also measured the serum
levels of leptin. Serum leptin was significantly lower in insulin
sensitive as compared to insulin resistant baboons and showed a
strong positive correlation with both FPG and liver TG content,
and was inversely correlated to hepatic insulin clearance and
QUICKI. Since leptin is directly associated with the fat mass
content, we adjusted the correlation between liver TG content and
QUICKI and FPI for fat content and body mass index, and these
correlations remained statistically significant. This suggests that
liver TG content is a determinant of hepatic insulin resistance,
independent from body fat mass/degree of obesity. Interestingly,
also an association between MCP-1, insulin resistance and
circulating liver enzymes has been observed in baboons suggesting
that they could be susceptible to development of NASH, although
no histological data were provided in that study [49]. Our data in
relation to the levels of long chain polyunsaturated fatty acids (18:2
and 18:3) contrasts with previous observations in other murine
models where decreased concentrations of PUFA have been
described in NAFLD. We consistently found higher levels of
PUFA in obese insulin resistant baboons with hepatosteatosis.
Stearoyl-CoA desaturase-1 (SCD-1) activity has been shown to
play a central role in adaptation to hepatocellular injury in murine
models of NAFLD and the ratio between monounsaturated to
saturated NEFA has been hypothesized to reflect SCD-1 activity
[50,51]. However, SCD-1 activity and mRNA expression do not
correlate with human liver fat content, although there was a very
significant positive correlation between C18:0/C18:1 ratio and
liver fat [52]. Our data are also in line with a previous report in
patients with NASH and NAFLD in which an increase in
polyunsaturated fatty acid liver concentration was found. Howev-
er, in that report the relation between the liver TG content and
fatty acid composition profile in relation with hepatic and
peripheral insulin sensitivity as well as fat content and leptin
levels were not evaluated [53]. While triglycerides are thought to
represent an inert lipid species, LC-CoA esters are intermediary
Figure 5. Macro steatosis, micro steatosis and ballooning in
liver of insulin resistant baboons. Higher magnification of the liver
from the insulin resistant baboon in Figure 4C and 4D showing discrete
round lipid vacuoles within hepatocytes and ballooning (A&B). Focal
area of minimal hepatic steatosis (C) in a different insulin resistant
baboon ((BMI=26.1, QUICKI=0.291, M=1.89 mgNkg/min
21).
doi:10.1371/journal.pone.0027617.g005
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synthesis of bioactive lipid species. LC-CoA esters lie at the
crossroads of b-oxidation and mitochondrial energy production,
and for the synthesis of lipid species (e.g. DAG and ceramides) that
are proposed to induce hepatic insulin resistance, as demonstrated
mainly, by studies in rodents [15,54,55,56]. Although, the precise
mechanisms behind the observed changes in LC-CoA concentra-
tions reflect complex and competing processes, these changes can
provide novel clues to altered mitochondrial energy production
and lipid-mediated insulin resistance in humans.
Circulating IGF-1 levels are significantly lower in patients with
NAFLD as compared to healthy controls [57]. Consistent with this
recent observation, we also found a modest, although non
significant decrease in circulating IGF-1 in IR as compared to
IS animals, further emphasizing that non-human primates could
be suitable models for NAFLD. In summary, hepatic triglyceride
accumulation in obese baboons is a major determinant of hepatic
insulin resistance. Furthermore increases in LC-SFAs as well LC-
UFAs are also highly associated with markers of adiposity and
decreased insulin sensitivity in liver and muscle. Overall, our
results suggest that there are multiple abnormalities in fatty acid
metabolism in obese IR baboons. Baboons are natural model for
the study of insulin resistance and NAFLD, suited for mechanistic
studies as well as to test novel dietary and pharmacological
interventions. Future studies will address the molecular defects in
hepatic insulin signaling and fatty acid accumulation in the liver,
possibly in conjunction with lipidomic and proteomic analysis.
Supporting Information
Figure S1 Low levels of IGF-1 in insulin resistant
baboons. Circulating IGF-1 levels in IR (n=10) and IS
(n=10) baboons.
(TIF)
Table S1 Diet composition.
(DOC)
Table S2 Individual profiles (duplicate determinations)
of various LC-FACoA concentrations in liver from obese
insulin resistant vs. lean control (insulin sensitive)
baboons.
(DOC)
Table S3 Correlations between circulating IGF-1 levels
with clinical and biochemical indexes of insulin sensi-
tivity, and liver TG, SFAs, PUFAs contents.
(DOC)
Author Contributions
Conceived and designed the experiments: SK AOC RAD FF. Performed
the experiments: SK AOC FC GAH GAA IPR-S MET AR EJD GWC
RG-M LMJ-C VM AMP PBH RAB. Analyzed the data: SK AOC EJD
AG GWC FF AGC DT. Contributed reagents/materials/analysis tools: FF
RAD. Wrote the paper: AOC SK GWC AMD FF.
References
1. Lazo M, Clark JM (2008) The epidemiology of nonalcoholic fatty liver disease: a
global perspective. Semin Liver Dis 28: 339–350.
2. Angulo P (2007) Obesity and nonalcoholic fatty liver disease. Nutr Rev 65:
S57–63.
3. Moore JB (2010) Non-alcoholic fatty liver disease: the hepatic consequence of
obesity and the metabolic syndrome. Proc Nutr Soc 69: 211–220.
4. Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients
with nonalcoholic fatty liver disease. N Engl J Med 363: 1341–1350.
5. Bozzetto L, Prinster A, Mancini M, Giacco R, De Natale C, et al. (2011) Liver
fat in obesity: role of type 2 diabetes mellitus and adipose tissue distribution.
Eur J Clin Invest 41: 39–44.
6. Perseghin G (2011) Lipids in the wrong place: visceral fat and nonalcoholic
steatohepatitis. Diabetes Care 34 Suppl 2: S367–370.
7. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, et al. (2005)
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease:
sites and mechanisms. Diabetologia 48: 634–642.
8. Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, et al. (2009) Triglyceride
levels and not adipokine concentrations are closely related to severity of
nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver
Spring) 17: 1696–1701.
9. Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver
disease: biochemical, metabolic, and clinical implications. Hepatology 51:
679–689.
10. Gastaldelli A, Cusi K, Pettiti M, Hardies J, Miyazaki Y, et al. (2007)
Relationship between hepatic/visceral fat and hepatic insulin resistance in
nondiabetic and type 2 diabetic subjects. Gastroenterology 133: 496–506.
11. Roden M (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes–
pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2:
335–348.
12. Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, et al. (2006)
NAFLD in children: a prospective clinical-pathological study and effect of
lifestyle advice. Hepatology 44: 458–465.
13. Deivanayagam S, Mohammed BS, Vitola BE, Naguib GH, Keshen TH, et al.
(2008) Nonalcoholic fatty liver disease is associated with hepatic and skeletal
muscle insulin resistance in overweight adolescents. Am J Clin Nutr 88:
257–262.
14. Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, et al. (2010)
Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and
contributes to the natural history of non-alcoholic fatty liver disease in an obese
rodent model. J Hepatol 52: 727–736.
15. Erion DM, Ignatova ID, Yonemitsu S, Nagai Y, Chatterjee P, et al. (2009)
Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of
cAMP response element-binding protein. Cell Metab 10: 499–506.
16. Fabbrini E, Conte C, Magkos F (2009) Methods for assessing intrahepatic fat
content and steatosis. Curr Opin Clin Nutr Metab Care 12: 474–481.
17. Chavez AO, Lopez-Alvarenga JC, Tejero ME, Triplitt C, Bastarrachea RA,
et al. (2008) Physiological and molecular determinants of insulin action in the
baboon. Diabetes 57: 899–908.
18. Chavez AO, Gastaldelli A, Guardado-Mendoza R, Lopez-Alvarenga JC,
Leland MM, et al. (2009) Predictive models of insulin resistance derived from
simple morphometric and biochemical indices related to obesity and the
metabolic syndrome in baboons. Cardiovasc Diabetol 8: 22.
19. Guardado-Mendoza R, Davalli AM, Chavez AO, Hubbard GB, Dick EJ, et al.
(2009) Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell prolifer-
ation are determinants of islet remodeling in type-2 diabetic baboons. Proc Natl
Acad Sci U S A 106: 13992–13997.
20. Zhang X, Zhang R, Raab S, Zheng W, Wang J, et al. Rhesus macaques develop
metabolic syndrome with reversible vascular dysfunction responsive to
pioglitazone. Circulation 124: 77–86.
21. Seth D, Leo MA, McGuinness PH, Lieber CS, Brennan Y, et al. (2003) Gene
expression profiling of alcoholic liver disease in the baboon (Papio hamadryas)
and human liver. Am J Pathol 163: 2303–2317.
22. Wene JD, Barnwell GM, Mitchell DS (1982) Flavor preferences, food intake,
and weight gain in baboons (Papio sp.). Physiol Behav 28: 569–573.
23. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, et al. (1989)
Glucose and free fatty acid metabolism in non-insulin-dependent diabetes
mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:
205–213.
24. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, et al. (2000)
Quantitative insulin sensitivity check index: a simple, accurate method for
assessing insulin sensitivity in humans. Journal of Clinical Endocrinology and
Metabolism 85: 2402–2410.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985)
Homeostasis model assessment: insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabetologia 28:
412–419.
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver
disease. Hepatology 41: 1313–1321.
27. Neschen S, Morino K, Hammond LE, Zhang D, Liu ZX, et al. (2005)
Prevention of hepatic steatosis and hepatic insulin resistance in mitochondrial
acyl-CoA:glycerol-sn-3-phosphate acyltransferase 1 knockout mice. Cell Metab
2: 55–65.
28. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003)
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatol-
ogy 37: 917–923.
29. Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the
metabolic syndrome. Arterioscler Thromb Vasc Biol 28: 27–38.
30. Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human
disease. Diabetes 37: 1595–1607.
Hepatic Fatty Acids and Insulin Resistance
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e2761731. Velloso LA, Folli F, Sun XJ, White MF, Saad MJ, et al. (1996) Cross-talk
between the insulin and angiotensin signaling systems. Proc Natl Acad Sci U S A
93: 12490–12495.
32. Cobbold JF, Anstee QM, Goldin RD, Williams HR, Matthews HC, et al. (2009)
Phenotyping murine models of non-alcoholic fatty liver disease through
metabolic profiling of intact liver tissue. Clin Sci (Lond) 116: 403–413.
33. van Werven JR, Schreuder TC, Nederveen AJ, Lavini C, Jansen PL, et al. (2010)
Hepatic unsaturated fatty acids in patients with non-alcoholic fatty liver disease
assessed by 3.0T MR spectroscopy. Eur J Radiol 75: e102–107.
34. Hwang JH, Stein DT, Barzilai N, Cui MH, Tonelli J, et al. (2007) Increased
intrahepatic triglyceride is associated with peripheral insulin resistance: in vivo
MR imaging and spectroscopy studies. Am J Physiol Endocrinol Metab 293:
E1663–1669.
35. Perseghin G, Scifo P, De Cobelli F, Pagliato E, Battezzati A, et al. (1999)
Intramyocellular triglyceride content is a determinant of in vivo insulin
resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy
assessment in offspring of type 2 diabetic parents. Diabetes 48: 1600–1606.
36. Hodson L, Skeaff CM, Fielding BA (2008) Fatty acid composition of adipose
tissue and blood in humans and its use as a biomarker of dietary intake. Prog
Lipid Res 47: 348–380.
37. Peter A, Cegan A, Wagner S, Lehmann R, Stefan N, et al. (2009) Hepatic lipid
composition and stearoyl-coenzyme A desaturase 1 mRNA expression can be
estimated from plasma VLDL fatty acid ratios. Clin Chem 55: 2113–2120.
38. Elinav E, Ali M, Bruck R, Brazowski E, Phillips A, et al. (2009) Competitive
inhibition of leptin signaling results in amelioration of liver fibrosis through
modulation of stellate cell function. Hepatology 49: 278–286.
39. Friedman SL (2004) Mechanisms of disease: Mechanisms of hepatic fibrosis and
therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1: 98–105.
40. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115: 209–218.
41. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, et al. (1999)
Insulin and insulin-like growth factor-1 stimulate proliferation and type I
collagen accumulation by human hepatic stellate cells: differential effects on
signal transduction pathways. Hepatology 29: 1743–1751.
42. Konner AC, Bruning JC (2011) Toll-like receptors: linking inflammation to
metabolism. Trends Endocrinol Metab 22: 16–23.
43. Kotronen A, Seppanen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, et al.
(2010) Comparison of lipid and fatty acid composition of the liver, subcutaneous
and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring) 18:
937–944.
44. Pettinelli P, Videla LA (2011) Up-Regulation of PPAR-{gamma} mRNA
Expression in the Liver of Obese Patients: an Additional Reinforcing Lipogenic
Mechanism to SREBP-1c Induction. J Clin Endocrinol Metab.
45. Riserus U, Basu S, Jovinge S, Fredrikson GN, Arnlov J, et al. (2002)
Supplementation with conjugated linoleic acid causes isomer-dependent
oxidative stress and elevated C-reactive protein: a potential link to fatty acid-
induced insulin resistance. Circulation 106: 1925–1929.
46. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, et al. (2003)
Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory
markers among US men and women. Circulation 108: 155–160.
47. Bueno AA, Oyama LM, de Oliveira C, Pisani LP, Ribeiro EB, et al. (2008)
Effects of different fatty acids and dietary lipids on adiponectin gene expression
in 3T3-L1 cells and C57BL/6J mice adipose tissue. Pflugers Arch 455: 701–709.
48. Wendel AA, Purushotham A, Liu LF, Belury MA (2008) Conjugated linoleic
acid fails to worsen insulin resistance but induces hepatic steatosis in the presence
of leptin in ob/ob mice. J Lipid Res 49: 98–106.
49. Bose T, Alvarenga JC, Tejero ME, Voruganti VS, Proffitt JM, et al. (2009)
Association of monocyte chemoattractant protein-1 with adipocyte number,
insulin resistance and liver function markers. J Med Primatol 38: 418–424.
50. Alkhouri N, Dixon LJ, Feldstein AE (2009) Lipotoxicity in nonalcoholic fatty
liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol
3: 445–451.
51. Li ZZ, Berk M, McIntyre TM, Feldstein AE (2009) Hepatic lipid partitioning
and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA
desaturase. J Biol Chem 284: 5637–5644.
52. Peter A, Cegan A, Wagner S, Elcnerova M, Konigsrainer A, et al. (2011)
Relationships between hepatic stearoyl-CoA desaturase-1 activity and mRNA
expression with liver fat content in humans. Am J Physiol Endocrinol Metab
300: E321–326.
53. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, et al. (2004)
Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to
hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond)
106: 635–643.
54. Li LO, Ellis JM, Paich HA, Wang S, Gong N, et al. (2009) Liver-specific loss of
long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-
oxidation and alters phospholipid fatty acid composition. J Biol Chem 284:
27816–27826.
55. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, et al. (2004) Mechanism of
hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:
32345–32353.
56. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, et al. (2007) Inhibition of
protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty
liver disease. J Clin Invest 117: 739–745.
57. Arturi F, Succurro E, Procopio C, Pedace E, Mannino GC, et al. Nonalcoholic
Fatty liver disease is associated with low circulating levels of insulin-like growth
factor-I. J Clin Endocrinol Metab 96: E1640–1644.
Hepatic Fatty Acids and Insulin Resistance
PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27617